LifeLoc Technologies Inc (LCTC)

[pdicamillo1]

Drug Screening Market Worth 8.63 Billion USD by 2022:

http://www.menafn.com/1096352721/about.html

Breathalyzers are expected to dominate the drug screening products market in 2017.

The Drug Screening Market is highly competitive with the presence of several small and big players. Some of the players offering products for Drug Screening Market include Alere (US), Thermo Fisher (US), Siemens Healthineers (US), Alfa Scientific Designs (US), Roche (Switzerland), MPD, Inc. (US), Shimadzu (Japan), OraSure (US), Lifeloc (US), and Drägerwerk (Germany). On the other hand, LabCorp (US), Quest Diagnostics (US), Psychemedics (US), Omega Laboratories (US), CRL (US), SureHire (Canada), and CannAmm (Canada).

Lifeloc technologies is in the top 10 for drug screening companies and this segment is expected to be worth close to $9 Billion in the next 5 years.

If Lifeloc were to capture only 1% of this market it would bring in revenues of $86 Million/year.

Lifeloc is currently valued at just $15 Million.

This stock is way undervalued here just from it's drug screening products division let alone the breathalyzer division.